drug

orelabrutinib

1 story · latest Nov 6, 2026

Follow orelabrutinib. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: Investigational
Trials: 2 registered trials in coverage

Relationships

Developed by Zenas BioPharma (USA), LLC

Timeline

Zenas files new $200M stock offering as obexelimab BLA review continues

Nov 6Financingobexelimab Zenas BioPharma (USA), LLCUpdated

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.